No approved antifibrotic drug exists on the market today
For decades, liver fibrosis has claimed hundreds of millions of lives in slow motion, advancing toward cirrhosis and cancer while medicine offered no approved remedy to slow its course. Now, researchers at China Pharmaceutical University have found that two familiar, inexpensive drugs — silybin and carvedilol — work in concert to suppress the molecular machinery driving the disease, achieving together what neither could accomplish alone. The discovery belongs to a tradition of finding new purpose in old tools, and it suggests that the long silence in antifibrotic medicine may finally be ready to break.
- Liver fibrosis affects hundreds of millions worldwide yet has no approved treatment, making every year of failed drug development a compounding human cost.
- The disease defeats single-drug approaches because multiple signaling pathways drive scarring simultaneously — block one, and the others carry the disease forward.
- Researchers screened 397 FDA-approved drugs paired with silybin and found carvedilol, a common heart medication, as its most potent synergistic partner against collagen-producing stellate cells.
- In animal models, the combination outperformed a leading comparison drug by targeting the Wnt4/β-catenin pathway from two angles at once, producing measurable reductions in fibrosis, inflammation, and liver injury.
- Because both drugs are already prescribed, cheap, and safety-tested, the road to human trials could unfold in months rather than the years required for novel compounds.
Liver fibrosis advances quietly. It moves through hundreds of millions of people — triggered by hepatitis, alcohol, metabolic disease, or autoimmune injury — until the liver's own healing response turns against it. Hepatic stellate cells wake from dormancy and begin manufacturing scar tissue. The organ stiffens. Function erodes. Cirrhosis and liver cancer wait at the end of the road. Despite decades of research, no antifibrotic drug has ever reached the market.
The disease has resisted treatment in part because it runs on multiple tracks at once. Signaling pathways like TGF-β, PDGF, and Wnt/β-catenin all drive the scarring process simultaneously, and blocking any single one has repeatedly proven insufficient. A team at China Pharmaceutical University, led by Hong Wang and Haiping Hao, decided to work with that complexity rather than against it — asking whether two existing drugs might succeed together where each had fallen short alone.
They screened 397 FDA-approved compounds in combination with silybin, a milk thistle derivative with modest liver-protective properties. Carvedilol, a beta-blocker prescribed for heart disease and hypertension, emerged as its most powerful partner. In cell cultures, the pairing sharply suppressed collagen production and stellate cell activation. In mice with chemically induced fibrosis, it outperformed obeticholic acid — a leading comparison drug — across measures of liver injury, inflammation, and fibrosis severity. The mechanism traced back to a shared suppression of the Wnt4/β-catenin signaling pathway, with both drugs inhibiting it from different angles and amplifying each other's effect.
The clinical promise lies as much in practicality as in biology. Both drugs are already widely used, inexpensive, and carry well-understood safety records. A fixed-dose combination at a 50:1 ratio of silybin to carvedilol produced the most stable results in animal models. Drug repurposing of this kind sidesteps years of toxicology work and regulatory groundwork — the path to human trials is measured in months, not decades. For a disease that has waited generations for a treatment, that compression of time carries real weight. The study also points outward: phenotype-based screening, testing drugs for unexpected synergies rather than intended purposes, may open similar doors for fibrotic diseases affecting the lungs, kidneys, and heart.
Liver fibrosis kills silently. It spreads through hundreds of millions of people worldwide, often unnoticed until the damage becomes irreversible—cirrhosis, liver cancer, organ failure. For decades, researchers have chased a cure. None has arrived. No antifibrotic drug exists on the market today, despite the scale of the problem and the urgency of the need.
The disease begins with injury: hepatitis, alcohol, metabolic disorder, toxins, autoimmune attack. The liver tries to heal itself, but something goes wrong. Specialized cells called hepatic stellate cells, normally dormant, wake up and transform into collagen factories. They pump out scar tissue. The liver stiffens. Function declines. The wound-healing response spirals into pathology. What makes fibrosis so difficult to treat is that it doesn't run on a single track. Multiple signaling pathways drive the process simultaneously—TGF-β, PDGF, Wnt/β-catenin. A drug that blocks one pathway often fails because the others keep the disease moving forward. This is why single-agent therapies have repeatedly disappointed.
A team at China Pharmaceutical University, led by Hong Wang and Haiping Hao, took a different approach. They asked whether two existing drugs, already prescribed for other conditions, might work together where neither worked alone. Silybin, a compound derived from milk thistle, had shown some promise in protecting liver cells from injury. Carvedilol, a beta-blocker used for heart disease and high blood pressure, was an unexpected candidate. The researchers screened 397 FDA-approved drugs in combination with silybin, testing each one's ability to suppress collagen production in hepatic stellate cells. Carvedilol emerged as the strongest synergistic partner—far more potent than either drug alone.
The mechanism revealed itself through careful laboratory work. In cell cultures, the combination markedly suppressed collagen production and HSC activation. In mice with chemically induced liver fibrosis, the pairing produced dose-dependent improvements in liver injury, inflammation, and fibrosis severity that exceeded a comparison drug, obeticholic acid. The synergy arose from a specific molecular cooperation: both drugs suppressed the Wnt/β-catenin signaling pathway, particularly by inhibiting a ligand called Wnt4 and its downstream effects. By hitting the same pathway from two angles simultaneously, they achieved what neither could accomplish alone.
What makes this discovery clinically significant is not just the mechanism but the practicality. Both silybin and carvedilol are already widely prescribed. Their safety profiles are well established. They are inexpensive. A fixed-dose combination at a ratio of 50:1 (silybin to carvedilol) produced the strongest and most stable effects in animal models. This is not a novel drug requiring years of toxicology studies and regulatory approval from scratch. This is drug repurposing—taking medicines already in use and finding new purpose in their combination. The path to human trials could be measured in months rather than years.
For a disease that has resisted treatment for generations, that represents a genuine shift. Hundreds of millions of people live with progressive liver fibrosis, watching their organ slowly harden, knowing that cirrhosis and cancer wait at the end of the road. No approved therapy exists to slow or reverse the process. This combination, if it performs in human patients as it has in laboratory models, could change that calculus. The study also demonstrates a broader principle: phenotype-based screening—testing drugs not for their intended purpose but for unexpected synergies—can unlock therapeutic combinations that rational drug design alone might never discover. Other fibrotic diseases, affecting other organs, may benefit from the same approach.
Citações Notáveis
The combination could move rapidly toward clinical testing, potentially addressing a major unmet medical need— Study findings
A Conversa do Hearth Outra perspectiva sobre a história
Why has liver fibrosis been so hard to treat, even after all these years of research?
Because the disease doesn't run on a single pathway. It's like trying to stop a fire by blocking one exit when there are five others burning. Fibrosis involves multiple signaling systems firing at once—TGF-β, PDGF, Wnt/β-catenin. A drug that shuts down one pathway often fails because the others keep the disease moving forward. That's why single-agent therapies have repeatedly disappointed.
So the idea here is to hit multiple pathways at once?
Exactly. But not with a new drug. With two old ones used together. Silybin protects liver cells from injury, but it doesn't directly stop the stellate cells from producing collagen. Carvedilol, a heart drug, turned out to be its perfect partner. Together, they suppress the same pathway—Wnt/β-catenin—from two different angles, creating a synergy neither achieves alone.
Why does that matter for patients?
Both drugs are already prescribed, already safe, already cheap. There's no need to spend a decade proving they won't poison people. You can move straight to human trials. For a disease with no approved treatment, that speed is everything.
What happens if it works in patients?
You've suddenly given hundreds of millions of people a way to slow or reverse a disease that was previously untreatable. Cirrhosis, liver cancer—those become preventable outcomes instead of inevitable ones. And you've also proven a method: phenotype-based screening can find unexpected drug combinations that rational design might never discover. That same approach could work for fibrosis in other organs.
Is there a catch?
The animal data is strong, but animal models don't always predict human response. You need to see whether the synergy holds in actual patients. That's the next step.